Table 2.

Grading of liver and lung inflammation and staging of liver fibrosis in vehicle-treated and imatinib-treated TSLP-Tg mice show significant reduction of inflammation and fibrosis in imatinib-treated TSLP-Tg mice in a time-dependent manner^a

Parameter	Time Course Study		Late Treatment Study
	TSLP-Vehicle	TSLP-Imatinib	TSLP-Control	TSLP-Imatinib
Liver injury
portal inflammation
2 wk	2.17 ± 0.40	1.33 ± 0.21b
4 wk	2.71 ± 0.44	1.125 ± 0.125c	1.56 ± 0.24	0.36 ± 0.14c
8 wk	3.14 ± 0.33	0.43 ± 0.17d
periportal injury
2 wk	2.00 ± 0.26	1.33 ± 0.21b
4 wk	2.28 ± 0.52	0.25 ± 0.25c	1.38 ± 0.25	0.29 ± 0.15b
8 wk	2.42 ± 0.40	0.14 ± 0.12d
parenchymal injury
2 wk	1.83 ± 0.31	0.66 ± 0.21e
4 wk	1.42 ± 0.28	0.63 ± 0.26b	1.06 ± 0.10	0.57 ± 0.20e
8 wk	1.71 ± 0.40	0.28 ± 0.15c
fibrosis
2 wk	2.00 ± 0.36	0.50 ± 0.17e
4 wk	2.42 ± 0.53	0.25 ± 0.16b	0.94 ± 0.18	0.43 ± 0.17e
8 wk	2.29 ± 0.24	0.14 ± 0.12d
Lung injury
inflammation
2 wk	2.50 ± 0.19	2.50 ± 0.19
4 wk	2.13 ± 0.21	1.38 ± 0.25e	2.19 ± 0.18	0.93 ± 0.20c
8 wk	2.36 ± 0.23	1.29 ± 0.17b

^aThe late treatment study, with mice treated for 4 wk beginning at day 90, also showed significant reductions in liver and lung inflammation. Data are means ± SEM; n = 6 to 8 mice per group;

Mann-Whitney test:

^bP < 0.01,

^cP < 0.001,

^dP < 0.0001,

^eP < 0.05: vehicle-treated TSLP tg mice vs imatinib-treated TSLP tg mice.